Business Description
Vera Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92337R1014
Share Class Description:
VERA: Class ATotal Employee Number:
339Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.76 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.21 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.1 | |||||
3-Year EPS without NRI Growth Rate | -11.9 | |||||
3-Year FCF Growth Rate | -13.9 | |||||
3-Year Book Growth Rate | 45.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.26 | |||||
9-Day RSI | 81.49 | |||||
14-Day RSI | 72.88 | |||||
3-1 Month Momentum % | -11.68 | |||||
6-1 Month Momentum % | -29.84 | |||||
12-1 Month Momentum % | 50.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.64 | |||||
Quick Ratio | 13.64 | |||||
Cash Ratio | 13.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.9 | |||||
Shareholder Yield % | -0.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -73.6 | |||||
ROA % | -60.23 | |||||
ROIC % | -5160.87 | |||||
3-Year ROIIC % | 36456.17 | |||||
ROC (Joel Greenblatt) % | -9810.28 | |||||
ROCE % | -63.03 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.12 | |||||
Price-to-Tangible-Book | 6.12 | |||||
EV-to-EBIT | -7.04 | |||||
EV-to-EBITDA | -7.05 | |||||
EV-to-Forward-Revenue | 43.47 | |||||
EV-to-FCF | -8.65 | |||||
| Price-to-Net-Current-Asset-Value | 6.2 | |||||
| Price-to-Net-Cash | 6.44 | |||||
Earnings Yield (Greenblatt) % | -14.2 | |||||
FCF Yield % | -9.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VERA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vera Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.54 | ||
| Beta | 2.6118 | ||
| 3-Year Sharpe Ratio | 0.78 | ||
| 3-Year Sortino Ratio | 2.52 | ||
| Volatility % | 69.7 | ||
| 14-Day RSI | 72.88 | ||
| 14-Day ATR ($) | 2.19719 | ||
| 20-Day SMA ($) | 35.722 | ||
| 12-1 Month Momentum % | 50.81 | ||
| 52-Week Range ($) | 19.0663 - 56.05 | ||
| Shares Outstanding (Mil) | 71.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vera Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vera Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 35 days | ||
| General meeting for 2026 | 2026-05-14 08:00 | 39.15 (+7.26%) | ||
| Guidance call for 2026 | 2026-05-13 16:20 | 36.70 (+0.99%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 36.60 (+4.80%) | ||
| Annual report for 2025 | 2026-02-26 | 41.68 (-2.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 41.68 (-2.23%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-13 14:15 | 46.46 (-4.38%) | ||
| Guidance call for 2025 | 2025-12-03 16:00 | 37.25 (+13.15%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-02 08:45 | 33.00 (-1.11%) |
Show
Entries
Vera Therapeutics Inc Frequently Asked Questions
What is Vera Therapeutics Inc(VERA)'s stock price today?
The current price of VERA is $42.66. The 52 week high of VERA is $56.05 and 52 week low is $19.07.
When is next earnings date of Vera Therapeutics Inc(VERA)?
The next earnings date of Vera Therapeutics Inc(VERA) is 2026-08-05 Est..
Does Vera Therapeutics Inc(VERA) pay dividends? If so, how much?
Vera Therapeutics Inc(VERA) does not pay dividend.
Guru Commentaries on NAS:VERA
No articles.
Press Release
Articles on Vera Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers